Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Conditions
Interventions
Belantamab mafodotin
Lenalidomide
+2 more
Locations
181
United States
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Beverly Hills, California, United States
GSK Investigational Site
Pasadena, California, United States
GSK Investigational Site
Aurora, Colorado, United States
GSK Investigational Site
Washington D.C., District of Columbia, United States
Start Date
December 16, 2024
Primary Completion Date
April 28, 2031
Completion Date
April 28, 2031
Last Updated
April 22, 2026
NCT05969860
NCT06057402
NCT06870760
NCT06383143
NCT07452198
NCT05243797
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions